Long Run Wealth Advisors’s GSK GSK Stock Holding History

Long Run Wealth Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-106,278	Closed	-$3.59M	–	104
2024 Q4	$3.59M	Buy	106,278 +20,355	+24%	+$733K	0.86%	38
2024 Q3	$3.51M	Buy	85,923 +3,380	+4%	+$138K	0.83%	39
2024 Q2	$3.18M	Buy	82,543 +1,537	+2%	+$64.7K	0.8%	37
2024 Q1	$3.47M	Buy	81,006 +2,786	+4%	+$115K	0.91%	33
2023 Q4	$2.9M	Buy	78,220 +6,401	+9%	+$230K	0.84%	34
2023 Q3	$2.6M	Buy	71,819 +4,664	+7%	+$166K	0.84%	31
2023 Q2	$2.39M	Buy	67,155 +4,708	+8%	+$169K	0.76%	37
2023 Q1	$2.22M	Buy	+62,447	New	+$2.18M	0.76%	39

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Long Run Wealth Advisors's GSK Position: Q1 2025 in Review

Long Run Wealth Advisors sold out of GSK (GSK) in Q1 2025, closing a stake of 106,278 shares — an estimated $3.59M sold.

Long Run Wealth Advisors first reported a position in GSK in Q1 2023 and held it in 8 quarters. The position peaked at $3.59M in Q4 2024. 857 funds tracked by Wall St. Rank hold GSK as of Q1 2025.

Long Run Wealth Advisors reported no remaining GSK position as of Q1 2025 after selling out during the quarter.
Long Run Wealth Advisors sold 106,278 GSK shares in Q1 2025, an estimated $3.59M.
Long Run Wealth Advisors first reported a position in GSK in Q1 2023 and held it in 8 quarters.
Long Run Wealth Advisors's GSK position peaked at $3.59M in Q4 2024.
857 funds tracked by Wall St. Rank held GSK as of Q1 2025.

Based on Long Run Wealth Advisors's 13F filing for Q1 2025, filed 10 Apr 2025.